Xenleta
These highlights do not include all the information needed to use XENLETA safely and effectively. See full prescribing information for XENLETA. XENLETA (lefamulin) injection, for intravenous use XENLETA (lefamulin) tablets, for oral use Initial U.S. Approval: 2019
101db63d-2fe2-48df-8506-1382d6dcd4a3
HUMAN PRESCRIPTION DRUG LABEL
Dec 28, 2022
Nabriva Therapeutics US, Inc.
DUNS: 072863844
Products 3
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
anhydrous citric acid
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (4)
lefamulin acetate
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (9)
lefamulin acetate
Product Details
FDA regulatory identification and product classification information